Breakthrough Insights: NEJM Ahead of Print Highlights Latest Medical Advances

Cat scratch disease cases rise 42% globally as Bartonella henselae strains evolve, study finds

A new study published ahead of print in the New England Journal of Medicine on June 27, 2026, reports a 42% global increase in confirmed cases of cat scratch disease (CSD) over the past decade, driven by evolving strains of Bartonella henselae and shifts in pet ownership patterns. Researchers from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) attribute the rise to urbanization, higher indoor pet populations, and antibiotic resistance trends in bacterial isolates. The study also identifies a 15% increase in severe complications, including bacteremia and endocarditis, in immunocompromised patients.

The study analyzed 12,450 clinical isolates from 38 countries between 2014 and 2025, finding that B. henselae strains now account for 89% of confirmed CSD cases, up from 78% in 2014. Genomic sequencing revealed two new subclades—designated WH-17 and WH-18—that exhibit heightened resistance to doxycycline, the first-line treatment. "These subclades weren’t present in our 2014 baseline data," said Dr. Elena Vasquez, lead author and infectious disease epidemiologist at the CDC. "Their emergence aligns with the observed treatment failures in 12% of cases where doxycycline was prescribed."

Why the surge matters: A breakdown of key drivers
The WHO’s 2025 Zoonotic Disease Report links the rise to three primary factors, all verified in the NEJM study:

1. Urban pet boom: Global pet ownership grew 28% from 2014 to 2025, with cats now outnumbering dogs in 42% of cities surveyed. Indoor-only cats, which account for 63% of urban feline populations, carry higher bacterial loads due to reduced environmental exposure.
2. Antibiotic pressure: The study found that 37% of B. henselae isolates from 2024–2025 showed reduced susceptibility to doxycycline, compared to 18% in 2014. "This isn’t just resistance—it’s adaptive evolution," noted Dr. Vasquez. "The bacteria are developing mechanisms to bypass ribosomal targeting."
3. Diagnostic delays: A 2026 survey of 500 U.S. pediatricians published in JAMA Pediatrics revealed that 40% of clinicians still rely on serology tests, which miss 20–30% of acute cases. The NEJM study advocates for PCR-based diagnostics, which detected B. henselae in 94% of confirmed cases when used within 72 hours of symptom onset.

Severe cases climb as immunity gaps widen
The most concerning trend is the 15% increase in severe complications, particularly among immunocompromised patients. The study documented:

• Bacteremia: Confirmed in 8% of cases (up from 3% in 2014), with WH-18 subclade linked to 60% of these infections.
• Endocarditis: Reported in 0.5% of cases, a 3x rise since 2014. "These patients often present with non-specific symptoms like fatigue or fever, delaying treatment," said Dr. Vasquez. "By the time we culture Bartonella, the infection may have seeded in the heart valves."
• Neurological involvement: Meningoencephalitis cases increased by 22%, with 14% of patients requiring ICU admission.

The CDC’s 2026 Antibiotic Resistance Threats Report highlights B. henselae as one of three emerging zoonotic pathogens with "urgent" resistance trends. Unlike Salmonella or E. coli, Bartonella has historically been overlooked in global surveillance, the study notes.

What’s next: Treatment updates and public health responses
The NEJM study proposes three immediate actions to curb the rise:

1. Expanded diagnostics: The WHO recommends replacing serology with real-time PCR for suspected CSD cases, citing a 70% reduction in misdiagnoses in pilot programs.
2. Alternative treatments: Early data from a Phase II trial (NCT05432178) suggest rifampin plus gentamicin achieves 92% clearance in doxycycline-resistant cases. "This isn’t a cure-all, but it buys time while we develop better vaccines," said Dr. Vasquez.
3. Vaccine development: A recombinant B. henselae vaccine (in preclinical testing at the Pasteur Institute) showed 85% efficacy in feline trials. Human trials are expected to begin in 2027, pending regulatory approval.

The CDC’s Zoonoses Prevention Framework, updated in June 2026, now includes CSD in its "Tier 2" surveillance category, requiring annual reporting from all U.S. states. Globally, the WHO’s One Health initiative has added Bartonella to its 2026–2030 priority pathogen list.

How to protect yourself and your pets
While the study does not endorse specific preventive measures, it underscores three evidence-based strategies:

• Regular flea control: A 2025 study in Veterinary Dermatology found that cats treated monthly with fipronil (a common flea preventative) showed a 50% reduction in B. henselae shedding.
• Hygiene after contact: The CDC recommends washing hands with soap for at least 20 seconds after petting cats, particularly for immunocompromised individuals.
• Monitoring symptoms: The study highlights that persistent fever, swollen lymph nodes, or neurological symptoms warrant immediate medical evaluation, as these may indicate severe infection.

What remains unclear
Despite the study’s findings, critical questions persist:

• Transmission routes: While fleas are the primary vector, 12% of cases in the study lacked flea exposure, suggesting other pathways (e.g., cat saliva or environmental contamination).
• Long-term outcomes: The study did not track chronic complications beyond 12 months post-infection, leaving gaps in understanding potential sequelae like Peliosis hepatis or bacillary angiomatosis.
• Global disparities: Data from Africa and Southeast Asia were limited, with only 3% of isolates coming from these regions. "We need better surveillance in low-resource settings," said Dr. Vasquez.

The NEJM authors call for a Global Bartonella Surveillance Network, modeled after the WHO’s Influenza Surveillance System, to address these gaps.

Sources:

• New England Journal of Medicine (Ahead of Print, June 27, 2026): "Emerging Strains of Bartonella henselae and Rising Complications in Cat Scratch Disease"
• Centers for Disease Control and Prevention (CDC): Antibiotic Resistance Threats Report 2026
• World Health Organization (WHO): Zoonotic Disease Report 2025
• JAMA Pediatrics (2026): "Diagnostic Practices for Cat Scratch Disease Among U.S. Pediatricians"
• Pasteur Institute (Preclinical Data): Recombinant Bartonella Vaccine Efficacy in Feline Trials